Gastroesophageal Reflux Disease (GERD) and Proton Pump Inhibitors (PPIs)

Deep Dive

GERD arises when the anti-reflux barrier at the gastroesophageal junction is compromised by transient lower esophageal sphincter relaxations, hy... GERD arises when the anti-reflux barrier at the gastroesophageal junction is compromised by transient lower esophageal sphincter relaxations, hypotensive sphincter tone, or anatomic disruption such as hiatal hernia. Gastric acidity, pepsin, and occasionally bile can contact the esophageal mucosa, leading to symptoms and mucosal injury. Population studies estimate a global prevalence near 13%, with heartburn and regurgitation as cardinal symptoms and recognized extra-esophageal manifestations (chronic cough, laryngitis, asthma flares, sleep disruption). In clinical practice, a short therapeutic trial of a proton pump inhibitor (PPI) is a common first step for typical symptoms without alarm features. PPIs irreversibly block the parietal cell H+/K+-ATPase, producing potent, sustained acid suppression. High-quality evidence shows PPIs outperform H2 receptor antagonists for healing erosive esophagitis and relieving symptoms over 4–8 weeks. Patients with severe erosive disease or Barrett’s esophagus often require long-term maintenance at the lowest effective dose; patients with non-erosive disease may do well with on-demand or step-down strategies. When symptoms persist despite optimized dosing and correct timing relative to meals, clinicians reassess adherence, consider alternative mechanisms (reflux hypersensitivity, functional heartburn, eosinophilic esophagitis), and use objective testing (endoscopy, ambulatory pH impedance monitoring). Lifestyle measures—weight loss in those with overweight or obesity, head-of-bed elevation, avoiding late meals, and individualized trigger management—have supportive evidence, particularly for nocturnal reflux. Adjuncts such as alginates can reduce postprandial reflux. Safety considerations with chronic PPI therapy are nuanced: common minor adverse effects include headache and gastrointestinal upset; observational data link PPIs with enteric infections (notably C. difficile) and suggest associations with fractures, chronic kidney disease, and micronutrient abnormalities (B12, magnesium), but causality is uncertain for several outcomes. The absolute risk increases are generally small. Rebound acid hypersecretion may produce transient symptom flare after stopping PPIs, so tapering and bridge strategies (H2 blockers, alginates, lifestyle) are often employed. Clinicians periodically reevaluate the indication and consider de-prescribing when appropriate; conversely, ongoing therapy is warranted for high-risk indications such as severe erosive esophagitis, strictures, or Barrett’s esophagus. Surgical options (fundoplication, magnetic sphincter augmentation) or endoscopic therapies are discussed for patients with proven reflux who remain symptomatic or prefer non-pharmacologic durable solutions.